絞り込み

16242

広告

Comparative Effects of Direct Renin Inhibitor and Angiotensin Receptor Blocker on Albuminuria in Hypertensive Patients with Type 2 Diabetes. A Randomized Controlled Trial.

著者 Uzu T , Araki SI , Kashiwagi A , Haneda M , Koya D , Yokoyama H , Kida Y , Ikebuchi M , Nakamura T , Nishimura M , Takahara N , Obata T , Omichi N , Sakamoto K , Shingu R , Taki H , Nagai Y , Tokuda H , Kitada M , Misawa M , Nishiyama A , Kobori H , Maega
PLoS One.2016 ; 11(12):e0164936.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (16view , 0users)
  • このエントリーをはてなブックマークに追加

Full Text Sources

In patients with diabetes, albuminuria is a risk marker of end-stage renal disease and cardiovascular events. An increased renin-angiotensin system activity has been reported to play an important role in the pathological processes in these conditions. We compared the effect of aliskiren, a direct renin inhibitor (DRI), with that of angiotensin receptor blockers (ARBs) on albuminuria and urinary excretion of angiotensinogen, a marker of intrarenal renin-angiotensin system activity.
PMID: 28033332 [PubMed - in process]
印刷用ページを開く Endnote用テキストダウンロード